Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423210 · ClinicalTrials.gov registry record · Early Phase 1
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
A Early Phase 1 study of Glioblastoma Multiforme, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05423210 is a Early Phase 1 study of Glioblastoma Multiforme that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 12 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05423210, a Early Phase 1 study of Glioblastoma Multiforme, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy and maximal safe resection as per normal care for a GB. After surgery patients will follow the normal care for glioblastoma in addition to Atezolizumab 840 mg IV q2 weeks for the duration of adjuvant treatment.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Atezolizumab + FSRT radiation
Study Locations (1)
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2029-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05423210
The ClinicalTrials.gov registry entry for NCT05423210 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (88% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab + FSRT radiation is the first listed.
NCT05423210 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05423210 about?
NCT05423210 is a clinical study titled "Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme". This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA appro...
What is the current status of trial NCT05423210?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2022-10-25. Estimated completion is 2029-08.
What conditions does trial NCT05423210 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT05423210?
The interventions under investigation include: Atezolizumab + FSRT radiation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05423210?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05423210 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of Pamiparib in Newly Diagnosed and rGBM
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.